Interferon-β_1b for multiple sclerosis

Abstract

Interferon-β_1b (Betaseron^®/Betaferon^®) was the first approved therapy for relapsing-remitting multiple sclerosis. The US Food and Drug Administration has expanded the indication to include relapsing forms of multiple sclerosis which encompasses secondary-progressive multiple sclerosis if relapses are present. In one scientifically sound head-to-head comparison (Independent Comparison of Interferon trial), interferon-β_1b was shown to be clinically superior to low-dose interferon-β_1a (Avonex™). Current studies are underway to compare it with a double dosage of interferon-β_1b as well as glatiramer acetate. Neutralizing antibodies are more likely to occur with interferon-β_1b, but their clinical significance has shown conflicting and confusing results making the utility of measuring neutralizing antibodies uncertain. Up to 12 years of follow-up data suggest that the drug remains effective on T2 magnetic resonance imaging burden of disease in those who stay on therapy. Initially, the major problem with interferon-β_1b was a lack of tolerability due to high incidents of skin reactions and influenza-like side effects. Patient adherence has improved dramatically with the introduction of autoinjectors and protocol changes including initial dose escalation, prophylactic ibuprofen or acetaminophen, evening administration of drug and an attentive nurse support system. Interferon-β_1b remains a first-line treatment for relapsing-remitting multiple sclerosis and relapsing forms of secondary-progressive multiple sclerosis based on robust efficacy data and a long-term safety profile.

Keywords::

• interferon-β1b
• multiple sclerosis
• neutralizing antibodies